With adherence to the tenet of “healing for life”, Zensun has long been focusing on the research of anti-tumor drugs and anti-heart failure drugs. Based on the innovative theory, Zensun has successfully developed two drugs: the Recombinant Human Neuregulin-1 injection, an anti-heart failure drug, and Recombinant Human ErbB3 fragment injection, a therapeutic vaccine against tumors, both have undergone clinical trial.

In 2006, Zensun (Shanghai) set up a subsidiary company, Zensun (USA), Inc., in San Diego, CA to manage FDA filing, clinical trials and commercialization process of Recombinant Human Neuregulin-1 (NeucardinTM), an exciting and novel treatment for heart failure (HF), as well as other compounds developed by Zensun (Shanghai). In 2009, Zensun (USA) was approved by the US FDA to conduct a Phase 2a US based trial of NeucardinTM administration to subjects with NYHA Class II and III Chronic Heart Failure.
Consistent with Zensun (Shanghai)’s mission, Zensun (USA)’s mission is: Innovation and Globalization.

• Innovation - Develop, manufacture and commercialize NEW therapeutic products with NOVEL mechanism.
• Globalization – Enter INTERNATIONAL pharmaceutical market to answer GLOBAL unmet medical needs.

Zensun USA’s current goal is to conduct clinical trials in the US. Zensun (USA)’s intermediate business objective is to establish or lease a cGMP manufacturing facility in USA for the manufacture and distribution of NeucardinTM in US and other international markets outside China.

The Management Team

Zensun (USA)’s management team is made up of industry veterans who have:

• Strong individual and collective expertise in molecular biology and cardiovascular research, showing capability for innovation.
• Full range of pre-clinical and clinical experience in novel drug development
• Valuable and extensive industry experience with demonstrated strong capability in project management, business development and financial management.

Zensun (USA) has also assembled an international scientific advisory board including world-class scientists, experienced pharmaceutical executives, and successful entrepreneurs.? The Company is actively recruiting senior staff to take responsibilities in cGMP manufacturing, business development, marketing research and sales.
Currently the key team members are:
Dr. Mingdong Zhou Chairman and CEO
Dr. Xifu Liu resident
Dr. Xinyan Li Vice President
Dr. Bhawanjit Brar Senior Director For Product Development
The structure of Zensun (USA) is shown as follows.

Zensun USA’s organization structure

Innovation: Innovation remains the unexhausted source of the progress of Zensun!

Focus: Focusing on the research and development of novel drugs is vital to the rapid development 　　　 of Zensun!

Internationalization: The successful step up to the international pharmaceutical market is the long-　　　　　　　　　term goal of Zensun!